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Background
Syndecan-1 is a heparan sulfate proteoglycan expressed on plasma cells, especially mye-
loma cells, and can exist in serum as soluble syndecan-1 after shedding from the cell 
surface. Soluble syndecan-1 has been suggested to promote myeloma cell growth and 
to be an independent prognostic factor for multiple myeloma. We aimed to evaluate the 
effect of soluble syndecan-1 levels at the time of diagnosis and during therapy on ther-
apeutic response and prognosis for patients with multiple myeloma.
Methods
We analyzed soluble syndecan-1 levels in 28 patients with multiple myeloma and 50 nor-
mal controls, and compared its levels with Durie-Salmon stage and other markers of 
myeloma. In addition, we evaluated the therapeutic response and determined the 3-year 
survival rates of these patients. 
Results
We observed that the median soluble syndecan-1 level in myeloma patients was higher 
than that in the normal controls (P＜0.0001), and the soluble syndecan-1 levels in 21 
(75%) patients were higher than the cut-off level (162 ng/mL). Soluble syndecan-1 levels 
correlated with disease stage, percentage of plasma cells in the bone marrow, β2 micro-
globulin level, serum M-component concentration, and creatinine level. The baseline lev-
els of soluble syndecan-1 at the time of diagnosis in the patients who responded to chemo-
therapy were lower than those in the non-responders (P=0.04); however, the baseline 
level was not a significant predictor of therapeutic response. The 3-year overall survival 
rate of the patients with high soluble syndecan-1 levels at the time of diagnosis and 6 
months after chemotherapy was lower than the corresponding survival rates of the pa-
tients with low levels of soluble syndecan-1; however, the overall survival rate was not 
statistically significant.
Conclusion
The use of soluble syndecan-1 has limitations in the diagnosis of multiple myeloma. 
Soluble syndecan-1 levels correlate with known prognostic factors; however, we could 
not assess the prognostic value of high levels of soluble syndecan-1 at the time of diagnosis 
and after chemotherapy.
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INTRODUCTION
Multiple myeloma (MM) is characterized by the pro-
liferation of clonal plasma cells in the bone marrow (BM) 
and production of monoclonal immunoglobulins. Syndecan- 
1 (CD138) is a heparan sulfate-bearing proteoglycan ex-
pressed by both normal and myeloma plasma cells [1]. 
Syndecan-1 mediates cell-cell and cell-matrix adhesion of 
myeloma cells and inhibits the invasion of myeloma cells 
invasion into type I collagen [2, 3]. Therefore, the shedding 
of syndecan-1 from the cell surface may contribute to cell 
proliferation and dissemination. Syndecan-1 is cleaved from 
the surface of myeloma cells by metalloproteinases and can 
exist in serum as soluble form [4]. Patients with MM have 
been reported to have high serum levels of soluble synde-Korean J Hematol 2010;45:115-9.
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Fig. 1. Soluble syndecan-1 levels at diagnosis in 28 patients with 
multiple myeloma. Horizontal line denotes mean +2 SD (162 ng/mL) 
of 50 healthy controls (sensitivity, 75% and specificity, 94%).
can-1; these high levels can be attributed to a high percentage 
of plasma cells in the BM and high β2-microglobulin levels 
[5]. Although soluble syndecan-1 level has been shown to 
be an independent negative prognostic factor [5, 6], no study 
has evaluated the diagnostic and prognostic value of soluble 
syndecan-1 in Korean MM patients. The purpose of this 
study was to investigate the discriminatory value of synde-
can-1 by measuring the levels of soluble syndecan-1 in mye-
loma patients and normal controls, and to analyze the effect 
of soluble syndecan-1 levels on the prognosis for patients 
with multiple myeloma.
MATERIALS AND METHODS
1. Patients
We investigated 28 patients (16 men and 12 women; mean 
age, 64.6±8.8 years; range, 42-75 years) who were newly 
diagnosed with MM between March 2005 and December 
2007, and monitored these patients until March 2009. 
Peripheral blood and BM aspirates were obtained from the 
patients at the time of diagnosis; peripheral blood was also 
obtained 6 months after the initiation of chemotherapy. The 
blood and BM aspirates were centrifuged, and the serum 
samples thus obtained were stored at -70
oC until subsequent 
analysis. The following variables were investigated at the 
time of diagnosis: percentage of plasma cell in the BM; serum 
levels of β2 microglobulin; serum M-protein concentration; 
types of immunoglobulin (Ig) present; serum levels of cal-
cium, creatinine, and lactate dehydrogenase (LD); and free 
κ/λ light chain ratio. Furthermore, we performed chromo-
somal analyses of BM specimens. The patients with MM 
were grouped on the basis of MM stages determined using 
the Durie-Salmon staging system [7]. Serum samples obtained 
from 50 healthy individuals (mean age, 60.8±9.1 years; range, 
45-76 years, men:women ratio=29：21) were used as normal 
controls.
Seven MM patients received vincristine, adriamycin, and 
dexamethasone (VAD) therapy, while 21 patients received 
cyclophosphamide and prednisolone (CP) therapy. During 
the follow-up period, 1 MM patient received thalidomide, 
and 2 patients received thalidomide and bortezomib. Two 
MM patients underwent stem cell transplantation. Therapeu-
tic response was defined as at least a 50% reduction in serum 
M-protein concentration at 6 months after the initiation 
of chemotherapy [8], and the patients were further classified 
as responders and non-responders according to their ther-
apeutic response. Survival was measured from diagnosis to 
death or last follow-up.
2. Analysis of soluble syndecan-1 levels in the blood and BM 
The concentration of soluble syndecan-1 was measured 
using a commercially available human syndecan-1 enzyme- 
linked immunosorbent assay kit (Diaclone Research, Besan-
con, France). Baseline levels of soluble syndecan-1 were 
determined before treatment, and follow-up levels were 
measured 6 months after the initiation of chemotherapy. 
Briefly, 100 μL of serums and standards and 50 μL of diluted 
biotinylated antibody were added into pre-coated wells and 
incubated for 1 h at room temperature (RT). After 3 washes, 
100 μL of horseradish-peroxidase-streptavidin conjugate was 
added, and the plate was incubated for 30 min at RT. After 
washing, 100 μL of substrate was added, and the color was 
allowed to develop for 15 min. The reaction was stopped 
with H2SO4, and the absorbance was read at 450 nm. All 
samples were analyzed in duplicate. The standard curve was 
linear from 8 to 256 ng/mL; serum samples with concen-
trations higher than 256 ng/mL were diluted.
3. Statistical analysis
Intergroup comparisons were performed by using the 
Mann-Whitney U test. Correlation between parameters was 
estimated by the Pearson correlation coefficient method. 
Logistic regression analysis was performed to determine the 
efficacy of soluble syndecan-1 as a predictor of response 
to treatment and mortality. Survival curves were plotted 
using the Kaplan-Meier method, and the log-rank test was 
used to assess intergroup differences. P-values less than 0.05 
were considered statistically significant.
RESULTS
The median baseline levels of soluble syndecan-1 in the 
peripheral blood of patients with MM was 265 ng/mL (range, 
98-1,049 ng/mL), whereas that in the normal controls was 
81 ng/mL (range, 27-192 ng/mL); this difference was statisti-
cally significant (P＜0.0001). The soluble syndecan-1 levels 
in 21 patients (75%) were higher than the mean level + 
2 SD (＞162 ng/mL) of control group (Fig. 1). The median 
soluble syndecan-1 level in the BM of the control group 
patients was 563 ng/mL (range, 211-2,389 ng/mL), and the 
soluble syndecan-1 levels in the BM correlated with those 
in the blood (r=0.86; P=0.02).
The clinical characteristics of the 28 MM patients are Korean J Hematol 2010;45:115-9.
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Table 3. Median levels of soluble syndecan-1 and the degree of 
reduction (range) in soluble syndecan-1 levels in myeloma patients
receiving chemotherapy.
Soluble syndecan-1 
level (ng/mL) 
Responders
(n=20)
Non-responders
(n=8)
P
At the time of diagnosis 220 
(98–1,049)
337 
(265–785)
0.04
At follow-up after 6 months 97
(60–470)
266
(172–629)
0.002
Degree of reduction (%) 524 (13–74) 21 (8–35) 0.001
Table 2. Correlation of soluble syndecan-1 levels with prognostic 
parameters at the time of diagnosis in patients with multiple 
myeloma.
Soluble syndecan-1
r P
Calcium 0.06 0.80
Creatinine 0.41 0.04
Free κ/λ light chain ratio
κ type 0.35 0.24
λ type 0.08 0.77
Lactate dehydrogenase 0.31 0.04
β2-microglobulin 0.39 0.04
Percentage of plasma cells 0.34 0.047
in the bone marrow
Serum M-component 0.40 0.02
Abbreviation: r, correlation coefficient.
Table 1. Clinical characteristics of 28 patients newly diagnosed 
with multiple myeloma.
Number of 
Factor Percentage
patients
Age (＞60 years) 18 64.3
Sex (male/female) 16/12
Durie–Salmon stage
I3 1 0 . 7
II 11 39.3
III 14 50.0
Ig class
IgG 18 64.3
IgA 7 25.0
Light chain 3 10.7
Light chain κ/λ 14/14
Soluble syndecan-1 (＞162 ng/mL) 21 75.0
Calcium (＞10.4 mg/dL) 2 7.1
Creatinine (＞2.0 mg/dL) 4 14.3
β2-microglobulin (＞3.5 μg/mL) 15 53.6
Free κ/λ ratio (＜0.26 or ＞1.65) 26 92.9
Lactate dehydrogenase (＞460 IU/L) 10 35.7
Marrow plasma cell (≥30%) 15 53.6
Serum M-component (＞3 g/dL) 8 28.6
Lytic bone lesions 15 53.6
Response to chemotherapy
Responders 20 71.4
Non-responders 8 29.6
shown in Table 1. According to the Durie-Salmon staging 
system, 3 patients (10.7%) were graded as stage I MM; 11 
patients (39.3%), stage II MM; and 14 patients (50%), stage 
III MM. Intergroup differences with regard to the median 
soluble syndecan-1 levels in patients with different MM 
stages were significant (P=0.045). The median soluble synde-
can-1 level in patients with stage I/II MM was 186.5 ng/mL 
(range, 98-785 ng/mL) and that in patients with stage III 
MM was 349 ng/mL (range, 101-1,049 ng/mL).
The distribution of immunoglobulins in the patients was 
as follows: IgG, 64.3% (n=18) and IgA, 25% (n=7); 3 patients 
had light-chain disease (10.7%). The soluble syndecan-1 lev-
els in patients with IgG (median level, 264.5 ng/mL; range, 
98-528 ng/mL) were not different from those in patients 
with other immunoglobulins (median level, 269 ng/mL; 
range, 101-1,049 ng/mL). Lytic bone lesions were observed 
in 15 patients, and the median soluble syndecan-1 levels 
in the patients with lytic bone lesions was not significantly 
different from those in the patients without lytic bone lesions 
(306 ng/mL vs. 257 ng/mL; P=0.76). Chromosomal abnormal-
ities were observed in 4 patients (complex karyotype, 3 pa-
tients and marker chromosome, 1 patient), and the median 
soluble syndecan-1 levels in patients with normal karyotypes 
were not significantly different from those in patients with 
abnormal karyotypes (P=0.36).
Soluble syndecan-1 levels positively correlated with other 
parameters such as percentage of plasma cells in the BM 
(r=0.34; P=0.047), β2 microglobulin level (r=0.39; P=0.04), 
and serum M-protein concentration (r=0.40; P=0.02). In ad-
dition, soluble syndecan-1 levels were clearly correlated with 
creatinine (r=0.41; P=0.04) and LD (r=0.31; P=0.04) levels. 
However, soluble syndecan-1 levels did not correlate with 
the calcium level and free κ/λ light chain ratio (Table 2).
All 7 patients (100%) with low baseline levels of soluble 
syndecan-1 (≤162 ng/mL) responded to chemotherapy, but 
only 13 (61.9%) among the 21 patients with high baseline 
levels of soluble syndecan-1 (＞162 ng/mL) showed a ther-
apeutic response. However, the rate of therapeutic response 
in patients with low baseline levels of soluble syndecan-1 
was not significantly different from that in patients with 
high baseline levels of soluble syndecan-1 (P=0.07). After 
6 months, 14 (50%) of the 28 patients showed low levels 
of soluble syndecan-1. The median soluble syndecan-1 level 
at the time of diagnosis in the responders was significantly 
lower than that in the non-responders (P=0.04). The degree 
of reduction in soluble syndecan-1 levels after 6 months 
in the responders was greater than that in the non-responders 
(P=0.001) (Table 3).
However, analysis by univariate logistic regression re-
vealed that soluble syndecan-1 was not a significant predictor 
of therapeutic response (P=0.56). Other parameters such as 
serum creatinine level (P=0.13), β2 microglobulin level (P= 
0.44), serum M-component concentration (P=0.08), and the 
p e r c e n t a g e  o f  p l a s m a  c e l l s  i n  t h e  B M  ( P=0.66) were not 
significant predictors.Korean J Hematol 2010;45:115-9.
118 Ji Myung Kim, et al. 
Fig. 2. Kaplan-Meier survival curves for patients classified on the basis
of the soluble syndecan-1 levels at 6 months after treatment. The solid
line represents patients with low levels of soluble syndecan-1 (≤162
ng/mL), and the dotted line represents patients with high levels of 
soluble syndecan-1 (＞162 ng/mL) (P=0.08).
The median follow-up time for all patients was 25.5 months 
(range, 7.5-43 months). During follow-up, 5 patients died, 
and 3 patients were lost to follow up. The soluble syndecan-1 
levels at the time of diagnosis and 6 months after the diagnosis 
were not significant predictors of mortality (P=0.36; P=0.26), 
while the other parameters were not significant.
The 3-year overall survival rates in patients with high 
(＞162 ng/mL) and low levels of soluble syndecan-1 at diag-
nosis were 59% (21 patients; 5 deaths) and 100% (7 patients; 
no death), respectively; however, the difference between 
these survival rates was not significant (P=0.11). The 3-year 
overall survival rates in patients with high and low levels 
of soluble syndecan-1 after 6 months were 54% (14 patients; 
4 deaths) and 93% (14 patients; 1 death), respectively, but 
the difference between these rates was not significant 
(P=0.08) (Fig. 2). The 3-year overall survival rates in patients 
with less and more than 30% reduction in soluble syndecan-1 
levels were 65% (10 patients; 3 deaths) and 75% (18 patients; 
2 deaths), respectively, but the difference between these 
rates was not significant (P=0.18).
DISCUSSION
Syndecan-1 is expressed on mature plasma cells and can 
exist in the serum as soluble syndecan-1 after being shed 
from the cell surface. Soluble syndecan-1 is present in low 
levels in normal populations, but its levels have been reported 
to be elevated in myeloma patients [4]. In animal studies, 
high levels of soluble syndecan-1 have been associated with 
the growth and metastasis of tumors [9]. In this study, the 
median soluble syndecan-1 level in MM patients (265 ng/mL) 
was significantly higher than that in the normal controls. 
The median soluble syndecan-1 level in our study was lower 
than that (336 ng/mL) reported by Lovell et al. in a recent 
large study conducted in 324 patients [6], but it was higher 
than the levels reported by Siedel et al. and Kumar et al. 
(164 ng/mL and 158 ng/mL, respectively) [5, 10]. The differ-
ences in the median levels can be attributed to racial differ-
ences and the difference in the proportion of patients with 
stage III disease in this study (50% stage III), which was 
different from those reported by Lovell (stage III, 88% pa-
tients) and Siedel (stage III, 49% patients). 
In our study, soluble syndecan-1 levels were not elevated 
in all the MM patients, and soluble syndecan-1 levels in 
25% of the patients were within the normal range (18-162 
ng/mL). Among the 7 patients with normal levels of soluble 
syndecan-1, 6 patients had stage I or II MM, and only 1 
patient had stage III MM. This finding is consistent with 
those of previous studies, which reported that some myeloma 
patients had normal levels of soluble syndecan-1 at the time 
of diagnosis [5, 6, 10], and suggests that the changes in 
soluble syndecan-1 levels can be attributed to the disease 
stage. In this study, the sensitivity of soluble syndecan-1 
in patients with MM was 75%; therefore, soluble syndecan-1 
does not have adequate diagnostic value.
Previous studies have shown that soluble syndecan-1 levels 
correlated with those of other disease markers, and soluble 
syndecan-1 levels in myeloma patients were different from 
those with monoclonal gammopathy of unknown sig-
nificance [10-13]. Intergroup differences with regard to the 
median soluble syndecan-1 levels in patients grouped accord-
ing to the MM stages were significant; soluble syndecan-1 
levels in the blood correlated with those in the BM. These 
results suggest a causal relationship between the blood level 
of soluble syndecan-1 and tumor mass. However, the pres-
ence of abnormal karyotypes and various Ig subtypes did 
not affect the soluble syndecan-1 levels; although hypo-
diplody and the presence of non-IgG subtypes were reported 
to be prognostic factors for MM [14, 15].
Positive correlations have been reported between soluble 
syndecan-1 levels and those of other prognostic factors and 
markers of tumor burden [16, 17], such as percentage of 
plasma cells in the BM, β2 microglobulin level, and serum 
M-protein concentration. The levels of soluble syndecan-1 
have also been reported to be correlated with those of crea-
tinine, which in turn were associated with the severity of 
renal failure [18]. This finding is consistent with those of 
previous studies [5, 6, 10, 11] and suggests that soluble synde-
can-1 plays a role in myeloma progression and that soluble 
syndecan-1 level is an indicator of the severity of renal 
failure. However, predictive value of the levels of soluble 
syndecan-1 for therapeutic response and mortality has not 
yet been substantiated. 
Dhodapkar et al. [19] showed that the presence of synde-
can-1 on the cell surface can counteract bone destruction 
in murine BM cell cultures. However, in this study, soluble 
syndecan-1 levels in patients with lytic bone lesions were 
not different from those without lytic bone lesions and did 
not correlate with calcium concentration. Therefore, soluble 
syndecan-1 probably does not affect bone destruction. 
Previous studies have shown that the soluble syndecan-1 
level at the time of diagnosis is a powerful and independent Korean J Hematol 2010;45:115-9.
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prognostic factor for multiple myeloma [5, 6, 10]. In partic-
ular, the median survival time of patients with high levels 
of soluble syndecan-1 was lesser than that of patients with 
low levels of soluble syndecan-1. However, the survival rate 
of patients with high levels of soluble syndecan-1 was not 
significantly different from that of patients with low levels 
of soluble syndecan-1 (P=0.11); this finding may be explained 
by the smaller number of patients and shorter follow-up 
period in our study as compared to those in previous studies. 
In addition, in this study, the survival rate of patients with 
high levels of soluble syndecan-1 at the time of follow-up 
examination was lower than the corresponding rate of pa-
tients with low levels of soluble syndecan-1, although the 
difference was not significant (P=0.08). Thus far, no study 
has examined the relationship between the soluble synde-
can-1 levels at the time of follow-up examination and 
survival. The results of our study suggest that the soluble 
syndecan-1 level at the time of follow-up examination can 
be associated with prognosis for MM.
The difference between responders and non-responders 
with regard to the degree of reduction in soluble syndecan-1 
levels 6 months after chemotherapy was significant, and 
the median soluble syndecan-1 level at the time of diagnosis 
in the responders was significantly higher than that in the 
non-responders. However, the frequency of therapeutic re-
sponse in patients with high levels of soluble syndecan-1 
did not differ significantly from that in patients with low 
levels of soluble syndecan-1 (P=0.14), although all non-res-
ponders showed high levels of soluble syndecan-1 at the 
time of diagnosis. The degree of reduction in soluble synde-
can-1 level after 6 months was unrelated to any significant 
difference in survival rate (P=0.18). We did not statistically 
prove that a high level of soluble syndecan-1 at the time 
of diagnosis is associated with a therapeutic response, but 
the trend showed that the rate of therapeutic response in 
the patients with low baseline levels of soluble syndecan-1 
was higher than that in the patients with high baseline 
levels of soluble syndecan-1.
In conclusion, the use of soluble syndecan-1 as a tool 
for diagnosing MM has limitations. However, in this study, 
the soluble syndecan-1 level correlated with those of other 
disease markers and had some predictive value for response 
to chemotherapy. Further studies should be performed to 
investigate the prognostic value of soluble syndecan-1 levels. 
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